ArticleBlood advances2025

Real-world evidence of duvelisib and romidepsin in relapsed/refractory peripheral and cutaneous T-cell lymphomas.

Josie G Ford et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.